(Q37724570)

22 August 2017

1 reference

title

Ovarian cancer: the duplicity of CA125 measurement (English)

1 reference

22 August 2017

1 reference

Amer K Karam

1

1 reference

22 August 2017

Beth Y Karlan

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

6 April 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

6

1 reference

22 August 2017

335-339

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2010.44

22 August 2017

0 references

cites work

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Results from four rounds of ovarian cancer screening in a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Reactivity of a monoclonal antibody with human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Re: "clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation"

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

The CA 125 gene: an extracellular superstructure dominated by repeat sequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

CA 125: the past and the future

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

31 March 2020

12 December 2020

The second generation CA 125 assays.

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

A binding domain on mesothelin for CA125/MUC16

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Playing the waiting game ... the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Radical surgical procedure improves survival time in patients with recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Secondary cytoreduction for ovarian cancer following cisplatin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

CA125 response: can it replace the traditional response criteria in ovarian cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.44

Treatment of recurrent ovarian cancer.

31 March 2020

1 reference

12 December 2020

The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

1 reference

12 December 2020

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalu

1 reference

12 December 2020

Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings

1 reference

12 December 2020

Secondary cytoreductive surgery for recurrent epithelial ovarian cancer

1 reference

12 December 2020

Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum

1 reference

12 December 2020

10.1038/NRCLINONC.2010.44

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

0 references

1 reference